Amarin Corporation plc (AMRN) Bundle
An Overview of Amarin Corporation plc (AMRN)
General Summary of Amarin Corporation plc (AMRN)
Amarin Corporation plc, founded in 2002, is a biopharmaceutical company based in Dublin, Ireland, focusing on the development and commercialization of therapeutics to improve cardiovascular health. The company is best known for its flagship product, VASCEPA (icosapent ethyl), an omega-3 fatty acid used to reduce the risk of cardiovascular events in patients with elevated triglyceride levels.
As of 2024, Amarin's sales have been significantly impacted by generic competition in the United States. The company has expanded its market presence into Europe, Canada, and China, with VASCEPA being sold by prescription in these regions, contributing to its revenue streams.
Company's Financial Performance in the Latest Financial Reports
For the three months ended September 30, 2024, Amarin reported total revenue of $42.3 million, a decrease of 36% compared to $66.1 million in the same period of 2023. This decline was primarily due to a significant drop in U.S. sales of VASCEPA, which fell by 51% year-over-year, accounting for $30.6 million in U.S. product revenue.
During the nine months ended September 30, 2024, the total revenue was $166.3 million, down 28% from $232.2 million in 2023. U.S. product revenue for this period was $122.5 million, a decrease of 41% compared to $209.0 million in the same period of 2023. In Europe, product revenue increased to $9.7 million for the nine months ended September 30, 2024, up from $1.9 million in the previous year.
The company reported a net loss of $33.6 million for the nine months ended September 30, 2024, compared to a loss of $53.3 million in the same period of 2023. This resulted in a loss per share of $0.06 for the third quarter of 2024.
Introduction to Amarin Corporation as a Leader in the Industry
Amarin Corporation has established itself as a leader in the cardiovascular therapeutics market, particularly with its innovative product, VASCEPA. The company has a significant market share in the icosapent ethyl market, although it has faced challenges due to increased competition and pricing pressures. As of September 30, 2024, Amarin held approximately 50% of the U.S. icosapent ethyl market, down from 58% a year earlier.
Amarin's strategic focus for 2024 includes expanding its global footprint, enhancing pricing reimbursement strategies, and launching commercial operations in all remaining European markets. The company remains committed to addressing the significant global patient need for VASCEPA and advancing its commercial operations worldwide.
Mission Statement of Amarin Corporation plc (AMRN)
Mission Statement of Amarin Corporation plc (AMRN)
Amarin Corporation plc is committed to improving cardiovascular health and reducing cardiovascular risk through the commercialization and development of therapeutics. The company’s mission statement encapsulates its dedication to delivering innovative treatments that enhance patient outcomes and promote overall health.
Core Component 1: Improving Cardiovascular Health
Amarin's mission prioritizes improving cardiovascular health as its primary focus. This is exemplified by its flagship product, VASCEPA (icosapent ethyl), which is approved for reducing triglyceride levels in patients with severe hypertriglyceridemia. As of September 30, 2024, VASCEPA has generated significant revenue, with product revenue of $41.9 million for the third quarter of 2024, despite facing competition from generic alternatives.
| Metric | Value (Q3 2024) | Value (Q3 2023) | Change (%) |
|---|---|---|---|
| Product Revenue, Net | $41.9 million | $64.9 million | -36% |
| U.S. Product Revenue, Net | $30.6 million | $62.4 million | -51% |
| VASCEPA-branded Prescriptions | Decreased by 13% | Compared to Q3 2023 | N/A |
Core Component 2: Commitment to Innovation
Amarin's mission reflects a strong commitment to innovation in pharmaceutical development. The company invests significantly in research and development, with expenses totaling $14.9 million for the nine months ended September 30, 2024. This commitment is evident in the expansion of VASCEPA’s indications, including the REDUCE-IT trial, which demonstrated a reduction in cardiovascular events among high-risk patients.
Core Component 3: Global Access to Therapeutics
Amarin's mission statement emphasizes the importance of global access to its therapeutics. As of September 30, 2024, the company recorded $4.3 million in product revenue from European markets, highlighting its growing international presence. Furthermore, during the nine months ending September 30, 2024, licensing and royalty revenue increased by 25% to $21.8 million, demonstrating Amarin's successful collaborations with partners across various regions.
| Region | Product Revenue (Q3 2024) | Product Revenue (Q3 2023) |
|---|---|---|
| U.S. | $30.6 million | $62.4 million |
| Europe | $4.3 million | $0.8 million |
| Collaboration Partners | $6.9 million | $1.8 million |
Through its mission statement, Amarin Corporation plc outlines its strategic focus on improving cardiovascular health, fostering innovation, and ensuring global access to its therapies, all supported by robust financial performance metrics and a commitment to research and development.
Vision Statement of Amarin Corporation plc (AMRN)
Vision Statement Overview
Amarin Corporation plc (AMRN) aims to redefine standards in cardiovascular health through innovative solutions that enhance patient outcomes. The company’s vision is focused on leveraging scientific advancements and strategic collaborations to ensure broader access to its leading product, VASCEPA, while fostering a sustainable and responsible business model.
Innovation in Cardiovascular Health
Amarin is committed to continuous innovation within the cardiovascular space. In 2024, the company has made significant strides in clinical research and product development. The approval of VASCEPA under the REDUCE-IT indication in June 2024 underscores its dedication to advancing treatment options for high-risk cardiovascular patients. This milestone was achieved following the recognition of a $15 million milestone payment associated with the approval.
Global Expansion and Accessibility
Amarin's vision includes a robust strategy for global market penetration. As of September 30, 2024, the company reported $166.3 million in total revenue, with a notable increase in product revenue from international markets, recording $21.8 million in licensing and royalty revenue, compared to $17.5 million in the prior year. The expansion into Europe and partnerships in regions like China and Canada are critical to increasing accessibility to VASCEPA, aiming to mitigate cardiovascular risks on a global scale.
Commitment to Patient-Centric Solutions
Amarin places a strong emphasis on patient outcomes in its vision. The company’s focus on the unique needs of patients is reflected in its strategic initiatives, including the restructuring plan that aims to reduce operational costs by $50 million annually. This financial prudence allows for reinvestment into research and development, ensuring that Amarin can continue to provide effective solutions for cardiovascular health.
Sustainability and Corporate Responsibility
Amarin's vision also encompasses a commitment to sustainability and ethical practices. As of September 30, 2024, the company reported cash and cash equivalents of $156.9 million, ensuring liquidity to support its long-term sustainability initiatives. The company is focused on maintaining responsible supply chain practices and enhancing manufacturing efficiencies to minimize environmental impact while maximizing patient access to essential medications.
| Financial Metrics | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Total Revenue, Net | $42.3 million | $66.1 million | -36% |
| Product Revenue, Net | $41.9 million | $64.9 million | -36% |
| Licensing and Royalty Revenue | $446,000 | $1.1 million | -61% |
| Net Loss | $25.1 million | $19.3 million | +30% |
| Cash and Cash Equivalents | $156.9 million | $199.3 million | -21% |
Strategic Collaborations and Partnerships
Amarin’s vision includes forming strategic partnerships to enhance its market presence. Collaborations with third-party companies for the distribution of VASCEPA have led to growth in international markets, contributing to an increase in net product revenue outside the U.S. by $16.2 million. This collaborative approach is pivotal in addressing global cardiovascular health challenges and ensuring that patients have access to innovative treatments.
Research and Development Focus
The company’s commitment to research and development remains a cornerstone of its vision. For the nine months ended September 30, 2024, Amarin reported R&D expenses of $14.9 million, demonstrating its investment in the development of new therapies and improvements to existing products. This focus aims to position Amarin as a leader in cardiovascular innovation, continuously improving treatment options for patients worldwide.
Core Values of Amarin Corporation plc (AMRN)
Integrity
Integrity is a fundamental value at Amarin Corporation plc, emphasizing honesty and transparency in all dealings. This commitment is crucial for building trust with stakeholders, including patients, healthcare providers, and investors.
Amarin demonstrates its integrity through rigorous compliance with regulatory standards and ethical guidelines. For instance, the company adheres to strict reporting requirements set forth by the SEC, ensuring that all financial disclosures are accurate and timely. In the third quarter of 2024, Amarin reported a net loss of $25.1 million, reflecting its transparency in communicating financial health.
Innovation
Innovation drives Amarin's mission to improve cardiovascular health through its flagship product, VASCEPA. The company invests heavily in research and development, with R&D expenses amounting to $14.9 million for the nine months ended September 30, 2024.
In 2024, Amarin received regulatory approval in China for the REDUCE-IT indication, a significant milestone that showcases its innovative approach to expanding its market presence. This strategic move is expected to enhance product accessibility and bolster revenue streams.
Collaboration
Collaboration is key to Amarin's success, as the company partners with various stakeholders, including healthcare providers and distributors. In 2023, Amarin recognized licensing revenue of $21.8 million from its agreements, highlighting the benefits of strategic partnerships in driving growth.
Amarin's collaboration with Edding has been particularly fruitful, leading to increased market penetration in China. The company reported net product revenue of $8.2 million related to sales to Edding for the nine months ended September 30, 2024.
Accountability
Accountability at Amarin entails taking responsibility for its actions, particularly in financial reporting and operational performance. The company’s total liabilities stood at $219.2 million as of September 30, 2024, reflecting its commitment to managing financial obligations responsibly.
Amarin also emphasizes accountability in its corporate governance practices, ensuring that its board of directors actively monitors performance and compliance with ethical standards. The company has made significant strides in improving its financial health, with total stockholders’ equity reported at $531.4 million.
Patient-Centricity
At the heart of Amarin's operations is a commitment to patient-centricity. The company focuses on delivering effective treatments that enhance patient outcomes. As of September 30, 2024, Amarin had accumulated a substantial inventory of $224 million to meet market demands for VASCEPA.
Furthermore, Amarin conducts extensive outreach and education initiatives aimed at healthcare providers and patients, ensuring that they are well-informed about the benefits of VASCEPA in managing cardiovascular health. This commitment to patient education reinforces Amarin's role as a leader in the industry.
| Core Value | Description | Examples of Commitment | 2024 Financial Data |
|---|---|---|---|
| Integrity | Honesty and transparency in all dealings | Compliance with SEC regulations | Net loss of $25.1 million for Q3 2024 |
| Innovation | Driving improvements in cardiovascular health | R&D investments and regulatory approvals | R&D expenses of $14.9 million for 9 months ended September 30, 2024 |
| Collaboration | Partnering with stakeholders for growth | Licensing agreements and distributor partnerships | Licensing revenue of $21.8 million in 2023 |
| Accountability | Responsibility for actions and performance | Active monitoring by the board of directors | Total liabilities of $219.2 million as of September 30, 2024 |
| Patient-Centricity | Focus on enhancing patient outcomes | Outreach and education initiatives | Inventory of $224 million to meet demand |
Amarin Corporation plc (AMRN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Amarin Corporation plc (AMRN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Amarin Corporation plc (AMRN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Amarin Corporation plc (AMRN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.